Kailera Therapeutics Raises $600 Million
Kailera Therapeutics, an obesity drug startup, has secured $600 million in funding from investors.
The financing round, led by Bain Capital's private equity group, included investments from Royalty Pharma and sovereign wealth funds in Canada and Qatar, as well as additional funding from Kailera's founding investors.
This significant investment highlights the ongoing interest in weight loss drugs, despite past clinical disappointments.
- Kailera's Series B round was announced nearly a year after the startup launched with $400 million.
- The deal follows Pfizer's announcement to acquire Metsera, a privately held obesity drug developer, for $4.9 billion.
No direct quote available in the text.
Author's summary: Kailera Therapeutics raises $600 million in funding.